Dr. Tom McFarlane teaches oncology, internal medicine, and immunology topics to the undergraduate students at the School of Pharmacy. He has a particular interest in GI, lung, and prostate cancers, and conducts practice based research in these settings which includes exploring ways of improving supportive care regimens for patients and the impact of supportive care on overall outcomes. He is also interested in qualitative research examining patient attitudes toward cancer care.
Office: PHR 5008
Phone: 519-888-4567, ext.21370
- Impact of pharmacist interventions on patient safety and adherence in oncology
- Complementary and alternative medicine in oncology
- Usage patterns of oncology and supportive care agents
- Cancer immunotherapy and vaccines
- Biosimilars in oncology
Research and Clinical Practice
Dr. McFarlane teaches at the undergraduate level. Course offerings have included:
PHARM 491, Seminars in Pharmacy 3
PHARM 475, Advanced Pharmacotherapeutics in the Ambulatory Care Setting (coordinator)
PHARM 464, Advanced Therapeutic Concepts in Oncology (coordinator)
PHARM 428, Professional Practice 4/High-stakes OSCE exam coordinator
PHARM 421, Integrated Patient Focused Care 8
PHARM 377, Drug Induced Disease
PHARM 320, Integrated Patient Focused Care 5 (coordinator)
Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak K. ASCO, NCCN, MASCC/ESMO: A Comparison of Antiemetic Guidelines for the Treatment of Chemotherapy Induced Nausea and Vomiting in Adult Patients. Support Care Cancer 2018; https://doi.org/10.1007/s00520-018-4464-y [Epub ahead of print]
McKenzie E, Zaki P, Raman S, Olson R, McFarlane T, DeAngelis C, Chan S, Pidduck W, Rasvi Y, Bushehri A, Chow E. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer 2018; https://doi.org/10.1007/s00520-018-4586-2 [Epub ahead of print]
Cowley EC, McFarlane TR. Treatment options for patients with mantle cell lymphoma post-transplantation: A scoping review of the literature. Eur J Oncol Pharm 2018; 1(4): e0006. http://dx.doi.org/10.1097/OP9.0000000000000006.
Richard CL, Lillie E, Mathias K, McFarlane T. Peer review of teaching in a Canadian pharmacy school: attitudes and impact on teaching practice. Am J Pharm Educ 2018; https://doi.org/10.5688/ajpe6828 [Epub Ahead of Print]
T McFarlane, C Girolametto, A Granic, J Lounsbury, S Hubay. A pilot study of a nurse and pharmacist led OTN (Ontario Telemedicine Network) based clinic for management of prostate cancer patients on oral therapy. Asia Pac J Clin Oncol 2018;14(Supp S7):198. doi: 10.1111/ajco.13089.
Jennifer Curran, Thomas McFarlane. Pharmacists’ Attitudes and Perceptions Regarding Natural Health Product Use in Oncology: A Cross-Sectional National Survey. J Oncol Pharm Practice 2018; 24(5 supp):28.
Tara Leslie, Tina Crosbie, Thomas McFarlane, Randy McFadyen, John Wiernikowski. Educational Impact and Registrant Perspectives for an Online Fundamental Oncology Pharmacy Conference in Canada. J Oncol Pharm Practice 2017; 23(4 supp):38.
Zargar M, McFarlane T, Chan KKW, Wong WWL. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. The Oncologist 2017; 23(2):225-233. doi: 10.1634/theoncologist.2017-0277
Professional Associations and Service
Dr. McFarlane is currently Science Teaching Fellow at the school of Pharmacy. He sits on the Assessment and Petitions Committees at the school and the Advisory Committee on Research Space. He is also a member of the Canadian Association of Pharmacy in Oncology (CAPhO) Education Committee and the CAPhO Undergraduate Education Subcommittee. In addition to these roles, he is the Chair of the CAPhO Research Committee and a member of the CAPhO Board of Directors, and is a member of the Cancer Care Ontario Genitourinary Cancers Site Group Formulary Advisory Committee.
The following news stories have featured Dr. McFarlane's research:
1996 BScPhm (University of Toronto)
2011 PharmD (Idaho State University)